FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD

　　On July 24,2026,Outlook Therapeutics,Inc.announced that the U.S.Food and Drug Administration(FDA)has approved Lytenava™(bevacizumab-vikg)for the treatment of neovascular age-related macular degeneration(nAMD),commonly known as wet AMD.This landmark approval represents a pivotal milestone in retinal care,delivering the first ophthalmic-grade bevacizumab formulation developed specifically for intravitreal administration after years of rigorous clinical and regulatory evaluation.

　　Closing a Two-Decade Gap

　　Wet AMD is a chronic,progressive retinal disease and one of the leading causes of severe vision loss among older adults worldwide.Patients typically require years of ongoing treatment to preserve vision,making manufacturing consistency,product quality,and long-term reliability critical throughout the treatment journey.

　　"For over two decades,bevacizumab has been one of the most widely used anti-VEGF therapies in retinal care,despite the absence of an FDA-approved ophthalmic formulation,"said Bob Jahr,CEO of Outlook Therapeutics."Lytenava fundamentally changes that landscape.Physicians no longer need to rely on repackaged formulations originally intended for intravenous use.They now have a bevacizumab product purpose-built for intravitreal delivery,with the manufacturing consistency,product quality,and regulatory oversight that patients deserve."

　　Mechanism of Action

　　Lytenava is a U.S.-manufactured ophthalmic bevacizumab formulation.Its active ingredient,bevacizumab-vikg(known as bevacizumab gamma in the EU and UK),is a recombinant humanized IgG1 monoclonal antibody that specifically targets human vascular endothelial growth factor(VEGF).It binds all VEGF-A isoforms,blocking their interaction with receptors VEGFR-1 and VEGFR-2,thereby inhibiting endothelial cell proliferation,neovascularization,and vascular permeability—the core pathophysiological processes driving vision loss.

　　Indication and Contraindications

　　Lytenava is indicated for the treatment of patients with neovascular(wet)age-related macular degeneration.It is contraindicated in patients with ocular or periocular infections,active intraocular inflammation,or known hypersensitivity to bevacizumab products or any component of Lytenava.Hypersensitivity reactions may manifest as severe intraocular inflammation.

　　Safety Considerations

　　Intravitreal injections are associated with risks of endophthalmitis and retinal detachment.Proper aseptic injection technique must always be employed,and patients should be monitored post-injection to enable early treatment if infection occurs.Transient increases in intraocular pressure have been observed within 60 minutes post-injection and should be monitored and managed appropriately.Although the incidence of arterial thromboembolic events(ATEs)was low in clinical trials,a potential risk exists with intravitreal VEGF inhibitors.

　　The most commonly reported adverse reactions(≥1%)were conjunctival hemorrhage(4%),eye pain(2%),and vitreous floaters(2%).